Stock Market Reviews

Read and share opinions on CLDX (Celldex Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

Latest News

• Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21
  Dec 21, 2025
• Celldex: Q3 Earnings Snapshot
  Nov 10, 2025
• Celldex Therapeutics (CLDX): Evaluating Valuation After Recent Share Price Weakness
  Nov 10, 2025
• Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
  Nov 10, 2025
• Celldex to Present at Upcoming Investor Conferences
  Nov 7, 2025
• Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
  Nov 6, 2025
• Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
  Oct 30, 2025
• Celldex Therapeutics (CLDX): Evaluating Valuation After Barclays' Underweight Rating and Industry Concerns
  Oct 23, 2025
• Barclays Initiates Coverage of Celldex Therapeutics (CLDX) With an Underweight Rating
  Oct 21, 2025
• Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
  Oct 10, 2025
• Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
  Sep 17, 2025
• Celldex Therapeutics (CLDX) Reports Promising Phase 2 Study Results For Barzolvolimab
  Sep 10, 2025
• Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
  Sep 9, 2025

CLDX News

• Celldex Therapeutics Stock Gets RS Rating Lift
  A Relative Strength Rating upgrade for Celldex Therapeutics shows improving technical performance. Will it continue?
  Dec 22, 2025
• Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21
  Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best small cap stocks to buy with huge upside potential. Barclays lifted the price target on Celldex Therapeutics, Inc. (NASDAQ:CLDX) to $24 from $21 on December 17 and reaffirmed an Equal Weight rating on the stock. The firm told investors that it adjusted the price targets in […]
  Dec 21, 2025
• We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely
  Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
  Dec 21, 2025
• Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
  No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in development to demonstrate clinical benefit in patients in ColdU and SD in a large, randomized, placebo-controlled study--all primary and secondary endpoints met with high statistical significance at 12 weeks and sustained through end of treatment period (20 weeks) in Phase 2 studyInitiation of EMBARQ-ColdU and SD marks second barzolvolimab
  Dec 9, 2025
• Celldex: Q3 Earnings Snapshot
  HAMPTON, N.J. (AP) — Celldex Therapeutics Inc. CLDX) on Monday reported a loss of $67 million in its third quarter. On a per-share basis, the Hampton, New Jersey-based company said it had a loss of $1.01.
  Nov 10, 2025
• Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control post treatment and strong efficacy regardless of baseline IgE levels Positive Phase 2 barzolvolimab data in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) demonstrating sustained efficacy and favorable safety profile at 20 weeks; first large, randomized, placebo-control
  Nov 10, 2025
• Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
  HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30 years of strategic, commercial launch and operating P&L leadership across the biopharmaceutical, medical device and consumer health technology sectors. Ms. Lawver succeeds Richard Wright, who will retire from Celldex following more than a decade of dedicated lead
  Nov 10, 2025
• Celldex Therapeutics (CLDX): Evaluating Valuation After Recent Share Price Weakness
  Celldex Therapeutics (CLDX) shares continued to show weakness as the stock was down 1.5% in Friday’s session and fell 14% over the past month. Recent trading activity has some investors reviewing its valuation in light of ongoing sector challenges. See our latest analysis for Celldex Therapeutics. Zooming out, Celldex Therapeutics’ share price has struggled to find its footing this year. The latest pullback continues a pattern of inconsistent performance. The 1-year total shareholder return...
  Nov 10, 2025
• Celldex to Present at Upcoming Investor Conferences
  HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11 at 10:00 am ETTD Cowen Immunology & Inflammation Summit on Thursday, November 13 at 9:30 am ET8th Annual Evercore Healthcare Conference on Tuesday, December 2 at 3:00 pm ET Live webcasts of the presentations will be available on the "E
  Nov 7, 2025
• Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
  HAMPTON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating barzolvolimab’s ability to improve urticaria control from the Company’s recently completed Phase 2 study in chronic spontaneous urticaria (CSU). The data (presentation #R080) are being presented at the American College of Allergy, Asthma & Immunology's Annual Scientific Meeting (ACAAI) in Orlando, Florida by Dr. Steven Greenberg, Vice President of
  Nov 6, 2025
• Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20
  First large, randomized, placebo-controlled study to demonstrate clinical benefit in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD)All primary and secondary endpoints met with high statistical significance at 12 weeks and sustained through end of treatment period (20 weeks)Up to 78% of patients with ColdU and 58% of patients with SD obtained a partial or complete response at Week 20Well tolerated through 20 weeks of dosingPhase 3 study in ColdU and SD to initiate in Dece
  Nov 6, 2025
• Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
  --Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—mast cell depletion via stem cell factor (SCF) starvation and neutralization of the alarmin thymic stromal lymphopoietin (TSLP). CDX-622 was well t
  Oct 30, 2025
• Celldex Therapeutics (CLDX): Evaluating Valuation After Barclays' Underweight Rating and Industry Concerns
  Barclays’ recent launch of coverage on Celldex Therapeutics (CLDX) assigned the stock an Underweight rating, drawing investor focus to both sector competition and questions about the safety profile of barzolvolimab. See our latest analysis for Celldex Therapeutics. After Barclays' cautious initiation, Celldex’s share price dipped over 4% in a day. The stock is still up more than 15% over the past three months. Despite some short-term turbulence, its one-year total shareholder return remains...
  Oct 23, 2025
• Barclays Initiates Coverage of Celldex Therapeutics (CLDX) With an Underweight Rating
  Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best small cap stocks with the highest upside. Barclays initiated coverage of Celldex Therapeutics, Inc. (NASDAQ:CLDX) with an Underweight rating on October 13, assigning a $25 price target to the shares. The rating came as part of the firm’s launch of eight companies across rare diseases, inflammation […]
  Oct 21, 2025
• Barclays initiates coverage on U.S. small & mid-cap biotech stocks
  Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market.
  Oct 13, 2025
• Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
  Here is how ANI Pharmaceuticals (ANIP) and Celldex Therapeutics (CLDX) have performed compared to their sector so far this year.
  Oct 10, 2025
• Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
  Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSUHAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients with chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity a
  Sep 17, 2025
• Celldex Therapeutics (CLDX) Reports Promising Phase 2 Study Results For Barzolvolimab
  Celldex Therapeutics (CLDX) experienced a share price increase of 19% over the last quarter, following significant developments in its clinical programs. Recently, the company announced promising results from a Phase 2 study of barzolvolimab, which showed effective mast cell depletion in eosinophilic esophagitis, albeit without clinical symptom improvement. Additionally, barzolvolimab demonstrated positive outcomes in treating chronic spontaneous urticaria. While Celldex's earnings faced...
  Sep 10, 2025
• Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
  HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conference at 3:20 pm ET. A live webcast of the presentation will be available on the "Events & Presentations” page of the "Investors" section of the Celldex website. A replay will be available for 90 days following the event. About CelldexCelldex is pioneering new h
  Sep 9, 2025
• Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma
  The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIndU is linked to conditions like allergies and autoimmune diseases. Market growth is propelled by insights into immune mechanisms and increasing awareness among healthcare providers. Emerging diagnostic tools and biologic therapies, such as monoclonal antibodies, enhance trea
  Aug 27, 2025
• FDA cancels adcomm on Biohaven drug; Catalent lays off staff
  Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff at a gene therapy facility.
  Aug 22, 2025
• LifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PT
  Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 12, Sam Slutsky from LifeSci Capital maintained a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of $74. The analyst noted that the company has shown progress in its pipeline. It is advancing its […]
  Aug 20, 2025
• Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
  Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a primary driver in EoE Favorable safety profile demonstrated for barzolvolimab 300 mg Q4 weekly dosing regimenCompany to host webcast today at 4:30 pm ET HAMPTON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today
  Aug 19, 2025
• Celldex Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
  Celldex Therapeutics ( NASDAQ:CLDX ) Second Quarter 2025 Results Key Financial Results Net loss: US$56.6m (loss widened...
  Aug 10, 2025

CLDX Reviews

• CapitalRush

  Dec 30, 2025

  $CLDX This firm is at the forefront of groundbreaking therapeutic solutions, aiming to address critical health challenges. The commitment to research and development demonstrates a promising trajectory for impactful advancements.

  Buy

• BuyLowBro

  Dec 30, 2025

  $CLDX If breakthroughs were pizzas, these folks are serving up the extra cheese with a side of innovation!

  Buy

• YieldHunter

  Dec 29, 2025

  $CLDX With a strong pipeline of therapeutic candidates and a focus on advancing treatment options, this biotech firm showcases promise in addressing significant medical needs. Their research endeavors could lead to impactful breakthroughs.

  Buy

• CashCombo

  Dec 29, 2025

  $CLDX Picture a scientist in a lab coat who’s also a stand-up comedian: this stock’s got potential but may have a few punchlines missing!

  Sell

• ChartSaber

  Dec 29, 2025

  $CLDX Innovative vibes in the biotech lane, they’re cooking up gold!

  Buy

• TickerTrickster

  Dec 28, 2025

  $CLDX Watch out, it's flexing hard in the biotech game, could be the next big thing!

  Buy

• StonkSamurai

  Dec 28, 2025

  $CLDX This one’s digging deep, looking for gold in the lab, keep an eye!

  Buy

• CashKiller

  Dec 28, 2025

  $CLDX A biotech with all the excitement of watching paint dry.

  Sell

• CapitalCrusher

  Dec 27, 2025

  $CLDX This stock sounds like the plot of a sci-fi movie. Let’s hope it doesn’t turn into a disaster flick!

  Sell

• LiquidKnight

  Dec 27, 2025

  $CLDX The race to break new ground in therapeutics is fierce! Will they emerge victorious or face setbacks that could spell disaster?

  Buy

• TradeGoblin

  Dec 25, 2025

  $CLDX Innovatin' in the lab, turning science into something real, watch out!

  Buy

• YieldMyth

  Dec 25, 2025

  $CLDX Pushing boundaries in treatment, this squad is ready to hustle!

  Buy

• TradeReckoner

  Dec 25, 2025

  $CLDX Still waiting for that breakthrough? Good luck!

  Sell

• StockNova

  Dec 24, 2025

  $CLDX Operating within the biopharmaceutical sector, this organization is engaged in the development of novel therapeutics. Their innovative pipeline may intrigue those interested in the cutting edge of medical advancements.

  Buy

• BagholderPrime

  Dec 23, 2025

  $CLDX It’s got more twists and turns than a mystery novel – you’ll be on the edge of your seat!

  Sell

• ProfitFang

  Dec 23, 2025

  $CLDX Focusing on novel immuno-oncology therapies, this firm is capitalizing on the growing demand for effective cancer treatments. With a robust pipeline, it appears well-positioned to make significant impacts in medical advancements.

  Buy

• StockNova

  Dec 22, 2025

  $CLDX By prioritizing breakthroughs in therapeutic solutions, this firm is at the forefront of addressing critical health challenges. Their pipeline suggests promising developments that may enhance their market reputation.

  Buy

• ChartPilot

  Dec 22, 2025

  $CLDX This stock is brimming with potential, yet it feels like a ticking clock. Every piece of news will send shockwaves—are you prepared for the fallout?

  Buy

• BuyLowBoi

  Dec 22, 2025

  $CLDX Biotech hustle is real, riding the wave of innovation with flair.

  Buy

• TheRiskDealer

  Dec 22, 2025

  $CLDX The highs and lows of clinical trials hit hard, leaving investors on a rollercoaster of emotions. Is the promise of innovation worth the potential heartbreak? Stay alert!

  Buy

• TrendHunter

  Dec 22, 2025

  $CLDX When your breakthroughs are just breakthroughs in bad luck.

  Sell

• MoonBagz

  Dec 21, 2025

  $CLDX They’re in the health game, lookin’ to shake things up.

  Buy

• RiskReaper

  Dec 21, 2025

  $CLDX This biotechnology firm is making headway in developing groundbreaking treatments for serious diseases. Its commitment to research and development, coupled with promising clinical trial results, underscores its potential to make a significant impact in the medical field.

  Buy

• MissionOverlord

  Dec 21, 2025

  $CLDX This one's got mad potential, watch it pop off soon!

  Buy

• MarketMarauder

  Dec 20, 2025

  $CLDX This therapeutic approach feels like snake oil.

  Sell

• PnLPhantom

  Dec 20, 2025

  $CLDX Research breakthroughs could be just around the corner, yet the pressure is intense! Every announcement feels like a ticking time bomb of expectations!

  Buy

• EquityPulse

  Dec 20, 2025

  $CLDX This stock is a pressure cooker! With every headline, the intensity ramps up, making it tough to breathe. What’s around the corner could change everything.

  Sell

• DividendHunter

  Dec 20, 2025

  $CLDX Sure, it exists, but does it really matter?

  Sell

• CapitalCreep

  Dec 20, 2025

  $CLDX Therapeutics? More like a therapy for your losing portfolio.

  Sell

• BagholderPrime

  Dec 20, 2025

  $CLDX If this stock were a superhero, its power would be making research cool again. Capes are optional!

  Buy

• MarketWolf

  Dec 20, 2025

  $CLDX With breakthroughs on the horizon, there's a palpable tension in the air. Can they turn this potential into profits before the clock runs out?

  Buy

• BullRunBoss

  Dec 20, 2025

  $CLDX This biotech company is like the kid in class who always has the coolest science projects. Future discoveries? Yes, please!

  Buy

• RiskWraith

  Dec 19, 2025

  $CLDX Innovations in therapeutics are thrilling, but with every step forward, the risks multiply! Can this company navigate the treacherous waters ahead?

  Buy

• ChartNomad

  Dec 19, 2025

  $CLDX In the race for biotech breakthroughs, will this firm find its niche or will it fizzle out like so many others before it?

  Sell

• ChartPilot

  Dec 19, 2025

  $CLDX Biotech stocks often feel like a gamble! One breakthrough could take it to the moon, but a setback could drag it down fast. Let's hope for some solid results soon!

  Buy

• RiskProtocol

  Dec 19, 2025

  $CLDX The tension is thick as this firm navigates turbulent waters. Breakthroughs could mean everything, yet the looming pressure to succeed amplifies the fear of failure. What will the next quarter hold?

  Buy

• StonkKnight

  Dec 19, 2025

  $CLDX This biotech's got the hustle to make waves in the lab!

  Buy

• TheStockKnight

  Dec 18, 2025

  $CLDX Chasing breakthroughs while everyone else runs ahead.

  Sell

• BearMarketSurvivor

  Dec 16, 2025

  $CLDX Ready to pop off, it’s makin’ waves in the game, no doubt!

  Buy

• StonkRider

  Dec 14, 2025

  $CLDX This company is at the forefront of innovative therapies and is making strides in targeted cancer treatments, showcasing strong potential in an evolving healthcare landscape. Its commitment to research and development positions it well for future growth.

  Buy

• GainVector

  Dec 13, 2025

  $CLDX Large liquidity void below.

  Sell

• TickerTrickster

  Dec 13, 2025

  $CLDX Short-term and long-term charts align bearish.

  Sell

• BagholderElite

  Dec 12, 2025

  $CLDX Technical setup favors sellers.

  Sell

• YOLOHold

  Dec 12, 2025

  $CLDX Positive reaction from buyers.

  Buy

• OptionRogue

  Dec 12, 2025

  $CLDX Momentum showing no signs of slowing.

  Buy

• MarketGlitch

  Dec 12, 2025

  $CLDX Chart looks primed for liftoff.

  Buy

• BearHunter

  Dec 12, 2025

  $CLDX Bearish dominance undeniable.

  Sell

• AlgoAce

  Dec 12, 2025

  $CLDX They’re on the cutting edge of science—like the kid who always tries new hairstyles before they’re cool!

  Buy

• VolatilityNomad

  Dec 12, 2025

  $CLDX Macro risk hurting momentum.

  Sell

• ShortSqueezeX

  Dec 12, 2025

  $CLDX Bullish reaction at key price zone.

  Buy

• ChartCrusher

  Dec 12, 2025

  $CLDX If only they could cure their own financial issues.

  Sell

• EquityAssault

  Dec 11, 2025

  $CLDX Trying to make waves but sinking fast.

  Sell

• TradeMatrix

  Dec 11, 2025

  $CLDX Great bullish structure emerging.

  Buy

• AlphaStriker

  Dec 11, 2025

  $CLDX Sell volume dominating heavily.

  Sell

• TheLongPlay

  Dec 11, 2025

  $CLDX Fantastic bullish structure.

  Buy

• BearEater

  Dec 11, 2025

  $CLDX Bearish channel developing.

  Sell

• TradeProtocol

  Dec 10, 2025

  $CLDX These folks are like a secret lab experiment – sometimes genius, sometimes scary, but always intriguing to watch unfold!

  Buy

• TradeTracer

  Dec 10, 2025

  $CLDX Focusing on innovative therapeutics to address unmet medical needs, this company is at the forefront of significant advancements in healthcare, showcasing potential for impactful contributions to patient outcomes.

  Buy

• OptionNomad

  Dec 10, 2025

  $CLDX Every hint of new data sends shivers down the spines of investors! The stakes are high, and with every trial, the tension builds—will this be the breakthrough, or another letdown?

  Buy

• BullishMyth

  Dec 9, 2025

  $CLDX Volume favors sellers overwhelmingly.

  Sell

• OptionShadow

  Dec 9, 2025

  $CLDX Momentum oscillators showing bullish divergence.

  Buy

• MarginBeast

  Dec 8, 2025

  $CLDX Promising science, but who are we kidding? It's as useful as a screen door on a submarine.

  Sell

• RiskAssassin

  Dec 8, 2025

  $CLDX The race against time in biotech can be nail-biting! Every trial outcome can either lead to breakthroughs or disastrous setbacks that shake investor confidence to its core.

  Buy

• BullRunBandit

  Dec 7, 2025

  $CLDX Watch out! This crew's cooking up something big!

  Buy

• MoneyMage

  Dec 7, 2025

  $CLDX Still waiting for a breakthrough while competitors sprint ahead.

  Sell

• RocketDividend

  Dec 7, 2025

  $CLDX In the game for some serious breakthroughs, watch this crew drop heat in biotech!

  Buy

• FinTechFrost

  Dec 6, 2025

  $CLDX Price action heavily one-sided.

  Sell

• YieldWarden

  Dec 6, 2025

  $CLDX With the clock ticking, this one seems to be teetering on the brink. Rumors swirl, and uncertainty mounts. Will it break through or crumble under pressure? It's a nail-biter for sure!

  Sell

• MarketRender

  Dec 5, 2025

  $CLDX The tension is palpable! With clinical trials looming, the stakes are high—will they breakthrough or face another setback? Investors are biting their nails watching this one!

  Sell

• GainSurge

  Dec 4, 2025

  $CLDX With breakthroughs in therapeutics on the line, the stakes couldn't be higher! Will they emerge as a pioneer or stumble amidst the competition? Investors are biting their nails!

  Sell

• CandleKnight

  Dec 4, 2025

  $CLDX Innovative vibes here, pushing the limits in biotech, feeling fresh!

  Buy

• CryptoCoyote

  Dec 4, 2025

  $CLDX Innovations are expected, yet the clock is ticking ominously. Investors are anxiously awaiting news; will it offer hope or despair?

  Buy

• HODLzilla

  Dec 4, 2025

  $CLDX Breakout confirmation almost here.

  Buy

• AlphaRogue

  Dec 4, 2025

  $CLDX Market signaling deeper correction.

  Sell

• BearMarketSurvivor

  Dec 4, 2025

  $CLDX Bearish retest rejection.

  Sell

• CapitalCreep

  Dec 3, 2025

  $CLDX Science or just another failed experiment? Who knows!

  Sell

• BullRaid

  Dec 3, 2025

  $CLDX Looks more like a science experiment gone wrong than a stock.

  Sell

• FiscalFrost

  Dec 3, 2025

  $CLDX Big money stepping in on the buy side.

  Buy

• RiskRanger

  Dec 3, 2025

  $CLDX Betting on this one feels like playing a game of hide and seek—except the only thing hiding is your patience!

  Buy

• MarginMyth

  Dec 2, 2025

  $CLDX Fighting for attention in a sea of underwhelming stocks.

  Sell

• TradeHex

  Dec 1, 2025

  $CLDX With a strong pipeline of immuno-oncology therapies, the potential for breakthrough treatments in cancer care is promising. The company's commitment to research and development could lead to significant advancements that may reshape patient outcomes.

  Buy

• MarketWolf

  Dec 1, 2025

  $CLDX What a rollercoaster! Just when you think you’ve got a grip, it takes a nosedive. I’m on the edge of my seat, anxiously waiting to see where this ride will end. It’s a nail-biter!

  Sell

• PnLReaper

  Nov 30, 2025

  $CLDX With a focus on developing cutting-edge therapeutics, this company is at the forefront of addressing unmet medical needs. The potential breakthroughs in its pipeline could have significant implications for patient care.

  Buy

• ProfitFang

  Nov 29, 2025

  $CLDX The advancements in their research pipeline signal potential breakthroughs in treatment options, positioning the company as a notable force in the biotech industry. The enthusiasm around their innovation is palpable.

  Buy

• CapitalCrusher

  Nov 29, 2025

  $CLDX This company is like that friend who always brings snacks to the party—great at keeping things interesting in healthcare!

  Buy

• CashClown

  Nov 28, 2025

  $CLDX Got some good vibes, could surprise the haters!

  Buy

• ChartFang

  Nov 28, 2025

  $CLDX This biotechnology firm is dedicated to developing new therapeutic options, making meaningful progress towards addressing unmet medical needs, which could reflect positively on its future valuation.

  Buy

• TradeNinja

  Nov 28, 2025

  $CLDX This one's like a lab coat-wearing superhero, fighting disease one cell at a time. Who wouldn’t root for that?

  Buy

• MarketWolf

  Nov 27, 2025

  $CLDX Chasing breakthroughs in therapeutics is exhilarating, but one miscalculation could send investors spiraling. Can they deliver when it matters most? The stakes are high!

  Sell

• TradeNinja

  Nov 27, 2025

  $CLDX This one is like that friend who always has the best snacks but never shares. Totally intriguing but also kinda selfish.

  Buy

• TickerTakedown

  Nov 25, 2025

  $CLDX This one’s like a mad scientist—always experimenting and trying to cure the world's problems!

  Buy

• AlphaDecoder

  Nov 25, 2025

  $CLDX As a biopharmaceutical company dedicated to developing immunotherapy treatments for cancer, this firm is positioned to make significant strides in the fight against disease. Its research initiatives showcase a strong commitment to innovation and patient-centered care.

  Buy

• BullishBerserker

  Nov 25, 2025

  $CLDX This company is navigating a maze of clinical trials and regulatory hurdles. Every announcement brings a rollercoaster of emotions—will they hit the mark or face setbacks again? It's a wild ride!

  Buy

• GammaSlayer

  Nov 25, 2025

  $CLDX This one's trying too hard to impress.

  Sell

• StonkDestroyer

  Nov 25, 2025

  $CLDX Too much hype, not enough results. Yawn.

  Sell

• MoonBagz

  Nov 24, 2025

  $CLDX Promising research, but can they turn hype into reality? Only time will tell.

  Sell

• StonkRider

  Nov 23, 2025

  $CLDX Driven by groundbreaking research in immuno-oncology, this company is making significant strides in the pharmaceutical landscape. Its focus on transformative therapies highlights a forward-thinking approach to treatment.

  Buy

• ChartPhantom

  Nov 23, 2025

  $CLDX This company is like a science fair project that actually turned out cool—who knew biology could be so profitable?

  Buy

• TradeProtocol

  Nov 23, 2025

  $CLDX Like a wild roller coaster ride—thrilling, kinda scary, but you’ll definitely want to go again!

  Buy

• OptionNomad

  Nov 22, 2025

  $CLDX Innovation is key, but can this stock stay ahead of the curve? One misstep and it could all come crashing down! The pressure is intense!

  Buy

• HedgeKnight

  Nov 22, 2025

  $CLDX They’re brewing science like coffee—strong and bold. This one might give you a buzz!

  Buy

• ShortKingston

  Nov 21, 2025

  $CLDX This stock is like that friend who always shows up to the party with snacks—everyone loves it, but you're not sure how long it’ll stick around!

  Buy

• ChartCrusher

  Nov 20, 2025

  $CLDX More like a rollercoaster with no safety bars.

  Sell

• TickerFlux

  Nov 20, 2025

  $CLDX Being involved with this stock is like being caught in a whirlwind. Just when you think you've got a handle on things, it whirls you around again! Are you prepared for the unexpected?

  Buy

• EarningsSync

  Nov 19, 2025

  $CLDX Innovation in biotech is thrilling, yet fraught with peril. Will they unleash a groundbreaking treatment or find themselves facing setbacks that could derail their progress? The pressure is intense!

  Buy

• ShortAndProud

  Nov 19, 2025

  $CLDX This crew's got some major moves in the biotech game, watch out!

  Buy

• AlphaRift

  Nov 19, 2025

  $CLDX Dedicated to advancing therapeutic solutions, this biotechnology firm emphasizes innovation and scientific excellence. Their strong pipeline and commitment to addressing unmet medical needs reflect a promising trajectory.

  Buy

• QuantSpecter

  Nov 18, 2025

  $CLDX This stock's potential hinges on unpredictable trial outcomes! It’s a constant battle against uncertainty, and investors are biting their nails waiting for results!

  Buy

• ChartFang

  Nov 18, 2025

  $CLDX Engaged in cutting-edge research and development, this company is making notable advancements in therapeutics. Their strong pipeline and commitment to addressing unmet medical needs could pave the way for significant breakthroughs.

  Buy

• WallStreetRogue

  Nov 18, 2025

  $CLDX In the race for breakthroughs in therapeutics, every setback feels monumental! This company is in a high-stakes game with lives on the line, and it keeps me on edge!

  Buy

• PortfolioFreak

  Nov 18, 2025

  $CLDX They’re making strides, but breakthroughs in biotech can be a double-edged sword. Are they ready for the rollercoaster of clinical trials?

  Sell

• TradeFrenzy

  Nov 17, 2025

  $CLDX Stumbling along with promises but no real results.

  Sell

• MarketPulseX

  Nov 17, 2025

  $CLDX With a strong emphasis on research and development, this biotech firm is at the forefront of innovation in therapeutics. The pipeline of products suggests a bright future, driven by scientific advancements.

  Buy

• TheEarningsBeast

  Nov 16, 2025

  $CLDX This company is all about breaking barriers! They’re like a scientist who just discovered that coffee can be good for you!

  Buy

• WallStreetVandal

  Nov 16, 2025

  $CLDX Therapeutics that promise miracles but deliver mediocre results.

  Sell

• PixelBroker

  Nov 16, 2025

  $CLDX Think of this one as a trendy coffee shop—everyone’s talking about it, but you’re just there for the free Wi-Fi!

  Sell

• ChartPhantom

  Nov 15, 2025

  $CLDX If this company were a superhero, it would totally wear a lab coat and save the day with cutting-edge science powers!

  Buy

• DividendJunkie

  Nov 15, 2025

  $CLDX Investing here is like watching grass grow, but slightly worse.

  Sell

• WallStreetBandit

  Nov 15, 2025

  $CLDX Another biotech gamble with no real payoff in sight.

  Sell

• VolatileViking

  Nov 14, 2025

  $CLDX They're on a mission to make science cool again! It's the nerdy stock that everyone secretly wants to hang out with!

  Sell

• ChartFang

  Nov 14, 2025

  $CLDX The ongoing research and development initiatives are indicative of a robust commitment to scientific advancement. This could lead to breakthroughs that not only enhance its portfolio but also elevate its market position.

  Buy

• TradeMatrix

  Nov 13, 2025

  $CLDX In the race against time for breakthroughs in therapeutics, every trial feels like a high-stakes gamble! With lives hanging in the balance, the pressure is relentless. Can they deliver or face a painful setback?

  Buy

• TradeRebel

  Nov 13, 2025

  $CLDX Navigating the complex landscape of therapeutics can feel like walking a tightrope! Innovations could lead to breakthroughs or massive setbacks. Will they deliver when it really counts?

  Buy

• MarginMythic

  Nov 12, 2025

  $CLDX With breakthroughs on the horizon, the stakes couldn't be higher. Will the upcoming trials deliver the results everyone is anxiously waiting for? The tension is palpable as investors hold their breath!

  Buy

• MoonBagz

  Nov 12, 2025

  $CLDX Pushing boundaries, definitely a player to keep an eye on.

  Buy

• BearWithMe

  Nov 12, 2025

  $CLDX Therapeutics are the future, watch for the next breakthrough!

  Buy

• ProfitVandal

  Nov 12, 2025

  $CLDX Looks promising until you peel back the layers of disappointment.

  Sell

• EquityEnigma

  Nov 11, 2025

  $CLDX Clinical trials are a rollercoaster ride! One day it’s promising news, the next it’s uncertainty. Get ready for some heart-pounding moments as the future unfolds.

  Buy

• LiquidityLord

  Nov 10, 2025

  $CLDX This company is poised to make significant strides in the biopharmaceutical sector, with a focus on innovative therapies that address unmet medical needs. Their commitment to research and development shows promise for future growth.

  Buy

• EquityPulse

  Nov 10, 2025

  $CLDX This biotech is fraught with pressure! New developments could either skyrocket or sink this stock, and the anticipation is almost unbearable as the clock ticks down to results!

  Buy

• TradeTracer

  Nov 10, 2025

  $CLDX This firm is at the forefront of groundbreaking medical research, developing potential therapies that could significantly impact patient care. Their robust pipeline and commitment to innovation make them a noteworthy contender in the biotech space.

  Buy

• TheFiscalShade

  Nov 9, 2025

  $CLDX This one's ready to pop like a fresh bag of popcorn at the movies!

  Buy

• GainsOverBrains

  Nov 9, 2025

  $CLDX They’re on the frontlines of breakthroughs, watch them shine.

  Buy

• MarketSavage

  Nov 9, 2025

  $CLDX A therapeutics company with more hopes than results.

  Sell

• EquityEnigma

  Nov 7, 2025

  $CLDX With the biotech sector buzzing, this company could be on the verge of a breakthrough or a massive setback. It's a rollercoaster ride that could either catapult your portfolio or leave it in shambles!

  Buy

• TheChartCode

  Nov 2, 2025

  $CLDX Chart's climbing like it heard good news from the universe. Green candles hitting different today.

  Buy

• HODLzilla

  Oct 31, 2025

  $CLDX lately a like clown looks

  Sell

• VolatilityNomad

  Oct 31, 2025

  $CLDX Honestly, I'm just here for the memes at this point.

  Sell

• ShortSurge

  Oct 18, 2025

  $CLDX levels check fire dripping soon humming trend eyes feels tax keeping sentiment nasty here run wild fast here

  Buy

• MarketReaper

  Oct 18, 2025

  $CLDX money gap keeping soon now sentiment whispers bull tape heat tbh tight whispers crushing hands hard range grind tbh spike sentiment hard on risk tax heating flows

  Buy

• TickerFlux

  Oct 13, 2025

  $CLDX trend hands eyes noise noise clean money levels watching fast heating hedges here imo theta choppy sauce hard range

  Sell

• ShortRaid

  Oct 5, 2025

  $CLDX Trend so clean even my chart indicators are blushing. If.

  Sell

• HedgeMeNot

  Oct 5, 2025

  $CLDX than deader eyes my crypto winter trend's deluxe chart dumpster fire this hurts

  Sell

• GainVector

  Oct 2, 2025

  $CLDX volume it's whispering so low

  Sell

• PnLReaper

  Sep 23, 2025

  $CLDX ruggy hard look no level-to-level sauce eyes hedges risk doom weak mode tax tight theta mess

  Sell

• TheEquityEdge

  Sep 18, 2025

  $CLDX Bulls and bears are just trading insults now. I blinked and lost.

  Sell

• TickerTrickster

  Sep 8, 2025

  $CLDX Even my coffee is less jittery than this price action.

  Sell

• ChartNomad

  Sep 7, 2025

  $CLDX Momentum so steady it could teach yoga. Whole market's giving 'we.

  Buy

• RiskWraith

  Sep 4, 2025

  $CLDX it's volume low whispering so

  Sell

• ShortSniper

  Aug 30, 2025

  $CLDX Market mood: confident with a hint of chaos. Momentum so clean I'd frame this chart.

  Sell

• TradePredator

  Aug 28, 2025

  $CLDX Technicals said no, emotions said yes - as usual. Volatility got me questioning my life choices.

  Sell

• BullishVanguard

  Aug 27, 2025

  $CLDX fast volume heavy trigger tight hurts dive macro mess noise here vibes humming flows whispers

  Sell

• GainVector

  Aug 20, 2025

  $CLDX warning fake should even come a rally

  Sell

• ShortSurge

  Aug 18, 2025

  $CLDX every bounce smells regret like gets instantly sold

  Sell

• OptionRogue

  Aug 16, 2025

  $CLDX Green candles hitting different today. I'm not saying it's mooning,.

  Sell

• TickerTyrant

  Aug 10, 2025

  $CLDX whispers rough my sentiment trend noise soon-ish earnings here whispers range supply it clear buzzing charts tax eyes spike

  Sell

• TickerTakedown

  Jul 9, 2025

  $CLDX bagholder ruggy look lows heavy now buzzing doom out risk hands

  Sell

• DividendDemon

  Apr 11, 2025

  $CLDX soon on steady smooth keeping strong alpha volume eyes levels theta heater level-to-level frankly now heavy breakout levels

  Buy

• BullishBerserker

  Apr 9, 2025

  $CLDX sentiment on dripping vibes trend queued fast heater no feels mooning heavy and loud it

  Buy

• YOLOTrader69

  Mar 26, 2025

  $CLDX frankly flows wall money fading weak wall soon-ish look ugly vibes

  Sell

• FinTechNomad

  Feb 13, 2025

  $CLDX eyes eyes now candle bagholder steady whispers mode trap session tax today trigger lower sentiment

  Sell

• FiscalBinary

  Sep 25, 2024

  $CLDX tax bagholder dead stops wall steady choppy out ruggy queued hurts

  Sell

• MarginBeast

  Aug 9, 2024

  $CLDX sentiment session trend talking hedges tape queued frankly choppy stops tax soon theta cliff mess

  Sell

• CodeAndCapital

  May 29, 2024

  $CLDX nasty spike flows hurts uptrend bounce no now dripping heat

  Buy

• OptionCipher

  Apr 26, 2024

  $CLDX ouch tape charts bear tape cliff heavy level-to-level mess theta

  Sell

• BullRunBoss

  Feb 14, 2024

  $CLDX clean noise cat steady steady soon patience out risk energy maybe liquidity mode buzzing

  Sell

• DividendJunkie

  Jan 23, 2024

  $CLDX soon heater today sentiment imo level-to-level gains whispers and steady eyes soon nasty oversold diamond

  Buy

• TraderFury

  Jan 6, 2024

  $CLDX sentiment bull staying strong check alpha and trigger clean clean sentiment

  Buy

• ShortSqueezeX

  Dec 19, 2023

  $CLDX rocket hurts volume range and bounce sentiment momentum vibes strong now

  Buy

• YOLOTrader

  Nov 27, 2023

  $CLDX feels here clean tax doom liquidity trap dead eyes energy eyes

  Sell